Fig. 2

Baseline plasma GFAP and NfL are elevated in FTD syndromes. a, b Comparison of baseline plasma GFAP (a) and NfL (b) between healthy controls or presymptomatic mutation carriers and all participants for a given symptomatic group. c, d Comparison of baseline GFAP (c) and NfL (d) between controls or presymptomatic carriers and participants in symptomatic groups with a CDR® + NACC-FTLD global score of 0 or 0.5. a-d Heat maps show AUCs comparing controls to the indicated groups that either include all individuals (All participants) or only those with an CDR® + NACC-FTLD global score of 0 or 0.5 (Mildly impaired participants) from unadjusted or age and sex-adjusted analyses. The number of participants (n) is shown. p values are from analysis adjusted for age and sex; p < 0.0071 (comparisons to controls) or p < 0.0083 (comparisons to presymptomatics) were considered statistically significant. ****p < 0.0001 and **p < 0.01 (comparison to controls); ^####p < 0.0001, ^###p < 0.001 and ^##p < 0.01 (comparison to presymptomatic mutation carriers). Horizontal bars represent median GFAP or NfL concentrations, which are shown on the base 2 logarithm scale. See Tables S8 and S9 relating to panels a and b, and Tables S14 and S15 relating to panels c and d